Chiraag Kapadia on Investigating Clonal Hematopoiesis After CAR T-cell Therapy


The MD, PhD candidate at Baylor College of Medicine discussed findings from a new study presented at the 2023 Tandem Meetings.

"CAR T treatments and cell therapies in general are becoming better and more curative. So now they're going to be a lot more patients that are in survivorship clinics, where there is a higher risk of getting secondary malignancies and cardiovascular events. So, we wanted to know if increased clonal hematopoiesis is potentially contributing to those survivorship effects.”

As outcomes improve in hematological malignancies with the help of cell therapies, including chimeric antigen receptor (CAR) T-cell therapies, questions remain about the long-term effects of such therapies in patients whose cancer has been eradicated. One such condition exacerbated by cytotoxic chemotherapy is clonal hematopoiesis (CH).

Researchers from Baylor College of medicine, including Chiraag Kapadia, MD/PhD candidate, GS4, investigated CH prevalence in 26 patients previously treated with CD30 CAR T-cell therapy for lymphoma and found that CH occurred frequently in these heavily pretreated patients and increased in clone size following CD30 CAR-T cell therapy. Kapadia presented these data at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19, 2023.

CGTLive spoke with Kapadia to learn more about CH and its potential effects in cancer survivors. He discussed the study’s findings, more research to be done, and why research post-cell therapy is important as survival past cell therapy starts to lengthen.

Kapadia CD, Rosas G, Tarrano V, et al. Longitudinal dynamics of clonal hematopoiesis in patients receiving anti-CD30 CAR T-cell therapy. Presented at: 2023 Tandem Meetings, February 15-18, 2023; Orlando, Florida. Abstract #49.
Related Videos
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
© 2024 MJH Life Sciences

All rights reserved.